FK317, a Novel Substituted Dihydrobenzoxazine, Exhibits Potent Antitumor Activity against Human Tumor Xenografts in Nude Mice

@inproceedings{Naoe1998FK317AN,
  title={FK317, a Novel Substituted Dihydrobenzoxazine, Exhibits Potent Antitumor Activity against Human Tumor Xenografts in Nude Mice},
  author={Yoshinori Naoe and Masamichi Inami and Sanae Matsumoto and Shoji Takagaki and Tomoichi Fujiwara and Sachiko Yamazaki and Ikuo Kawamura and Fusako Nishigaki and Susumu Tsujimoto and Toshitaka Manda and Kyoichi Shimomura},
  booktitle={Japanese journal of cancer research : Gann},
  year={1998}
}
The antitumor effects of FK317, a novel substituted dihydrobenzoxazine, were evaluated using human tumor xenografts (small cell lung cancer, non-small cell lung cancer, stomach cancer, colon cancer, pancreatic cancer, breast cancer, cervical cancer and ovarian cancer). Tumor growth-inhibitory effects and the effective dose-range of FK317 were much stronger and broader, respectively, than those of reference drugs such as mitomycin C, adriamycin, cisplatin, taxol and irinotecan. Furthermore, the… CONTINUE READING
2 Citations
26 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Preclinical pharmacology and toxicology of Taxotere (RP56976, NSC628503)

  • M. C. Bissery, A. Renard, S. Andre
  • Ann. Oncol. ,
  • 1992

Phase I clinical and pharmacokinetic study of FK973

  • H. Majima, K. Hasegawa, +8 authors H. Niitani
  • Proc. Am. Soc. Clin. Oncol
  • 1990

Similar Papers

Loading similar papers…